Journal of Biomedical Engineering Research (대한의용생체공학회:의공학회지)

The Korean Society of Medical and Biological Engineering (대한의용생체공학회)
권호 표지
DOI QR코드

DOI QR Code

A Comparative Study on the Regulations on Implantable Bioabsorbable Combination Products -Focusing on the U.S., Europe and Korea-

이식형 흡수성 융복합 의료제품 규제 비교 연구 -미국, 유럽, 한국을 중심으로-

  • Hyeon Jeong Lee (Regulatory Strategy center for Combination Product (RSCP)) ;
  • Mi Hye Kim (Regulatory Strategy center for Combination Product (RSCP)) ;
  • Ju Eun Seol (Regulatory Strategy center for Combination Product (RSCP)) ;
  • Su Dong Kim (Industry-Academic Cooperation Foundation, Ajou University) ;
  • Joo Hee Kim (Regulatory Strategy center for Combination Product (RSCP))
  • 이현정 (아주대학교 융복합의료제품 촉진지원센터) ;
  • 김미혜 (아주대학교 융복합의료제품 촉진지원센터) ;
  • 설주은 (아주대학교 융복합의료제품 촉진지원센터) ;
  • 김수동 (아주대학교 산학협력단) ;
  • 김주희 (아주대학교 융복합의료제품 촉진지원센터)
  • Received : 2023.11.10
  • Accepted : 2023.12.05
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Implantable bioabsorbable combination products undergo inherent degradation and systemic absorption within the physiological environment, thereby streamlining the therapeutic regimen and obviating the imperative for invasive extraction procedures. This inherent property not only enhances patient convenience and therapeutic efficacy but also underpins a paradigm of support characterized by heightened safety parameters. Within the regulatory landscapes of Korea, the United States, and Europe, implantable bioabsorbable combination products are meticulously classified into distinct categories, either as pharmaceutical implants or as implantable medical devices, depending on their primary mode of action. This scholarly investigation systematically examines the regulatory frameworks governing implantable bioabsorbable combination products in South Korea, the United States, and Europe. Notable discrepancies across national jurisdictions emerge concerning regulatory specifics, including terminology, product classification, and product name associated with these products. The conspicuous absence of standardized approval regulations presents a formidable barrier to the commercialization of these advanced medical devices. This academic discourse passionately emphasizes the critical need for formulating and implementing a sophisticated regulatory framework capable of streamlining the product approval process, thereby paving the way for a seamless path to commercializing implantable bioabsorbable combination products.

Keywords

Acknowledgement

본 연구는 식품의약품안전처의 「융복합 의료제품 안전기술 촉진지원 연구(식약처_21153 인프라431)」 연구 개발비로 수행되었으며 이에 감사드립니다.

References

  1. Saincher SS, Gottlieb C. Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. Journal of Ophthalmic Inflammation and Infection.2020;10(1):1.
  2. Stamer WD, Perkumas KM, Kang MH, Dibas M, Robinson MR, Rhee DJ. Proposed Mechanism of Long-Term Intraocular Pressure Lowering With the Bimatoprost Implant. Invest Ophthalmol Vis Sci. 2023;64(3):15.
  3. Suner IJ, Peden MC. Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy. Clin Ophthalmol. 2021;15:3859-3864. https://doi.org/10.2147/OPTH.S330255
  4. https://www.globenewswire.com/news-release/2020/04/08/2013787/0/en/Controlled-Release-Drug-Delivery-Market-Size-Share-Trends-Analysis-Report-By-Technology-By-Release-Mechanism-By-Application-By-Region-And-Segment-Fore-casts-2020-2027.html. Accessed on 12 Sep 2023.
  5. https://www.europeanpharmaceuticalreview.com/news/93077/controlled-release-drug-delivery-market-to-rise-14-3-percent/. Aceesed on 12 Sep 2023.
  6. Yang L, Yufeng Z, Hayesn B. Degradable, absorbable or resorb-able-what is the best grammatical modifier for an implant that is eventually absorbed by the body?. Science China Materials. 2017;60(5):377-391. https://doi.org/10.1007/s40843-017-9023-9
  7. Haner JD, Raber L, Windecker S, Biodegradable vs. permanent polymer drug-eluting stents: the need for a new nomenclature to classify drug-eluting stent technology. European Heart Journal. 2019;40(31):2616-2619. https://doi.org/10.1093/eurheartj/ehz330
  8. Ministry of Food and Drug Safety public Notification No. 2023-40;MFDS;2023.
  9. Ministry of Food and Drug Safety public Notification No.2023-39;MFDS;2023.
  10. https://www.usp.org/sites/default/files/usp/document/usp-nomenclature-guidelines.pdf. Accessed on 8 Sep 2023.
  11. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-801/subpart-A/section-801.3. Accessed on 8 Sep 2023.
  12. EUROPEAN PHARMACOPOEIA(Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease(COVID-19) pandemic); Council of Europe;2020.
  13. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745&qid=1701158537215. Accessed on 15 Sep 2023.
  14. Chu C. 11 - Materials for absorbable and nonabsorbable surgical sutures. In: King MW, Gupta B, Guidoin R. Biotextiles as Medical Implants 1st ed. Cabridge: Woodhead Publishing; 2013;275-334.
  15. Vert M, Yoshiharu D, Hellwich KH, Hess M, Hodge P, Kubisa P, Rinaudo M, Schue F. Terminology for biorelated polymers and applications (IUPAC Recommendations 2012). Pure and Applied Chemistry. 2012;84(2):377-410. https://doi.org/10.1351/PAC-REC-10-12-04
  16. ASTM F2092-16e1 Standard Guide for Assessment of Absorbable Polymeric Implants. 2017;15.
  17. ISO 10993-16:2017 Biological evaluation of medical devices, Part16:Toxicokinetic study design for degradation products and leachables. 2017;1-7.
  18. KS P ISO TR 37137:2014:Cardiovascular biological evaluation of medical devices-Guidance for absorbable implants. 2019;1-14.
  19. Williams DF. The Williams Dictionary of Biomaterials. Liverpool:Liverpool University Press. 1999;33-132.
  20. Ministry of SMEs and Startups. Translation of the European Medical Device Regulation(CE MDR). 2021;6-217.
  21. NIDS Innovative medical device Research and development information magazine Vol.15 -Medical devices using biodegradable materials in the body. 2021;2-23.
  22. Kim DC, Kwon JT, Jeong JH, Kim SM. Safety and Performance Evaluation Method of Implantable Medical Device Based on Advanced Technology. The Korean Society of Food, Drug and Cosmetic Regulatory Sciences. 2018;13(2):125-131.
  23. Baek MH, Jang SH, Lee ST, Kim JH. The Development of Biodegradable Medical Devices. The Korean Society of Manufacturing Process Engineers. 2022;4-4.
  24. Cho YT, Lee JY, Shim DY, Park SJ, Rhee HE, Sung HG, Kim HJ, Choi NK, Song HJ, Kim JA, Park SM, Shin JY. Comparison of Postmarket Surveillance Strategies of Implantable Medical Devices in the United States, European Union, and South Korea. Pharmacoepidemiology and Risk Management. 2021;13(2):45-54. https://doi.org/10.56142/2021.13.2.45
  25. NFDS Risk management based medical device biological evaluation guidelines;2022;28-39.
  26. ISO 10993-15:2019 Biological evaluation of medical devices, Part15: Identification and quantification of degradation products from metals and alloys. 2019;1-11.
  27. https://www.labiotech.eu/trends-news/polyganics-breakthrough-device-fda/. Accessed on 28 Oct 2023.
  28. https://www.novopedics.com/. Accessed on 28 Oct 2023.
  29. Selmin F, Musazzi U, Magri G, Rocco P, Cilurzo F, Minghetti P. Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies. Drug Discov Today. 2020;25(2):321-329. https://doi.org/10.1016/j.drudis.2019.12.008
  30. Fink M, Akra B, Comparison of the international regulations for medical devices-USA versus Europe. Injury. 2023;54(5):110908.
  31. https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program. Accessed on 28 Oct 2023.
  32. https://www.globenewswire.com/news-release/2019/09/17/1916556/0/en/Orchestra-BioMed-Announces-FDA-Breakthrough-Device-Designation-for-Virtue-Sirolimus-Eluting-Balloon-for-Treatment-of-Below-the-Knee-Peripheral-Artery-Disease.html. Accessed on 28 Oct 2023.
  33. MFDS Overseas Combination Product Approval and Review System -Europe-, 2021.
  34. https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng. Accessed on 15 Oct 2023.
  35. MDCG 2021-24, Guidance on classification of medical devices; Medical Device Coordination Group. 2021;54-56.
  36. NIFDS Medical Device Test Method Information Data Sheet - Performance evaluation of biodegradable synthetic polymer implantable medical devices considering the human implantation environment. 2023;1-18.
  37. Park CW, Park SH, Kim WC, Key JH. Stereocomplex Poly (lactic acid) Discoidal Microparticles for Sustained Drug Relese. Journal of Biomedical Engineering Research. 2020;41(1):62-66. https://doi.org/10.9718/JBER.2020.41.1.62
  38. Jung TG, Lee JH, Lee JJ, Hyon SH, Han DW. A Study on Effects of EGCG and Design Parameter for Drug-Eluting Biodegradable Polymer Stents. Journal of Biomedical Engineering Research. 2013;34(3):111-116. https://doi.org/10.9718/JBER.2013.34.3.111
  39. Veyssi A, Ogg H, Initiating a paradigm shift in American healthcare: Empowering women with implantable contraceptives. Journal of Drug Delivery Science and Technology, 2023;89:105075.
  40. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32021R2282. Accessed on 25 Oct 2023.